title: Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma.
abstract: A first step in primary disease prevention is identifying common, modifiable risk factors that contribute to a significant proportion of disease development. Infant respiratory viral infection and childhood asthma are the most common acute and chronic diseases of childhood, respectively. Common clinical features and links between these diseases have long been recognized, with early-life respiratory syncytial virus (RSV) and rhinovirus (RV) lower respiratory tract infections (LRTIs) being strongly associated with increased asthma risk. However, there has long been debate over the role of these respiratory viruses in asthma inception. In this article, we systematically review the evidence linking early-life RSV and RV LRTIs with asthma inception and whether they could therefore be targets for primary prevention efforts.
authors.affiliation: 1 Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, and Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tennessee.
authors.forename: Amy S
authors.initials: AS
authors.lastname: Feldman
authors.forename: Yuan
authors.initials: Y
authors.lastname: He
authors.forename: Martin L
authors.initials: ML
authors.lastname: Moore
authors.forename: Marc B
authors.initials: MB
authors.lastname: Hershenson
authors.forename: Tina V
authors.initials: TV
authors.lastname: Hartert
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D001249:Asthma / Q000235:genetics / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D002675:Child, Preschool; D004032:Diet; D004781:Environmental Exposure / Q000009:adverse effects*; D044127:Epigenesis, Genetic; D020022:Genetic Predisposition to Disease; D006801:Humans; D007223:Infant; D064307:Microbiota / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D000069455:Palivizumab; D011322:Primary Prevention / Q000379:methods; D018357:Respiratory Syncytial Virus Infections / Q000150:complications* / Q000188:drug therapy / Q000235:genetics / Q000276:immunology; D012136:Respiratory Syncytial Viruses / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D012141:Respiratory Tract Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D012229:Rhinovirus / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D012307:Risk Factors; D012720:Severity of Illness Index; D014028:Tobacco Smoke Pollution / Q000009:adverse effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D014028:Tobacco Smoke Pollution; D000069455:Palivizumab
keywords: RSV; RV; asthma; respiratory syncytial virus; rhinovirus